Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Nasal vaccination of triple-RBD scaffold protein with flagellin elicits long-term protection against SARS-CoV-2 variants including JN.1

Fig. 2

Long-lasting RBD-specific antibodies responses and antibody secreting cells in BALB/c mice. a Diagram scheme of immunization and sampling (n = 5 mice per group). b RBD-specific IgA responses in saliva and vaginal lavage fluid post the 2nd immunization. c Geometric mean titers of neutralizing antibody in serum against pseudo-typed SARS-CoV-2 variants or SARS-CoV-1 at day 14 post the 3rd immunization. d–f RBD-specific serum IgG, serum IgG1, serum IgG2a, salivary IgA and vaginal IgA were measured at various time points post 3rd immunization. g RBD-specific IgG and IgA in nasal wash at 13 months post 3rd immunization. ELISPOT assayed RBD-specific IgG and IgA secreting cells at 13 months (h, j, l) and 10 days (i, k, m) post 3rd immunization of 3R-NC + KFDi.n and 3R-NC + ALi.m. Data are represented as mean ± SEM and are representative of two independent experiments. Groups were compared using one-way ANOVA. *p < 0.05; **p < 0.01; ***p < 0.001; ns non-significant

Back to article page